



US007619004B1

(12) **United States Patent**
Davis

(10) **Patent No.:** **US 7,619,004 B1**
(45) **Date of Patent:** ***Nov. 17, 2009**

(54) **METHODS FOR CONCOMITANT
ADMINISTRATION OF COLCHICINE AND
MACROLIDE ANTIBIOTICS**

(75) Inventor: **Matthew W. Davis**, Erwinna, PA (US)

(73) Assignee: **Mutual Pharmaceutical Company,
Inc.**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **12/327,258**

(22) Filed: **Dec. 3, 2008**

Related U.S. Application Data

(60) Provisional application No. 61/190,053, filed on Oct.
15, 2008.

(51) **Int. Cl.**
A61K 31/167 (2006.01)
C07C 233/23 (2006.01)
C07C 211/41 (2006.01)

(52) **U.S. Cl.** **514/629**; 564/123; 564/308;
564/427; 568/306

(58) **Field of Classification Search** 514/629;
564/123, 308, 427; 568/306
See application file for complete search history.

(56) **References Cited**

OTHER PUBLICATIONS

Concomitant_drugs (wikipedia document).
Morris et al. BMJ vol. 327, 2003, p. 1275-76.
Caraco, et al; "Acute Colchicine Intoxication—Possible Role of
Erythromycin Administration"; Journal of Rheumatology; 19; pp.
494-496; (1992).
Horn, et al.; "Life-Threatening Colchicine Drug Interactions"; Phar-
macy Times; p. 111; (May 2006).
Perez-Ruiz, et al.; "Optimisation of the Treatment of Acute Gout";
BioDrugs; 13; pp. 415-423; (2000).
Rollot, et al.; "Acute Colchicine Intoxication During Clarithromycin
Administration"; The Annals of Pharmacotherapy; 38; pp. 2074-
2077; (2004).

Terkeltaub, Robert A.; "Gout"; The New England Journal of Medi-
cine; 349; pp. 1647-1655; (2003).

Van Der Velden, et al.; "Colchicine-Induced Neuromyopathy in a
Patient with Chronic Renal Failure: The Role of Clarithromycin";
Netherlands Journal of Medicine; 66; pp. 204-206; (2008).

Waknine, Yael; "FDA Safety Changes: Dexedrine and Biaxin CME/
CE"; Medscape Medical News; [http://bcbsma.medscape.com/
viewarticle/54411](http://bcbsma.medscape.com/viewarticle/54411); 5 pages; (2006).

Terkeltaub, et al.; "Comparison of Low-Dose vs High-Dose Oral
Colchicine Regimens in Patients with Gout Flares"; Presentation at
the American College of Rheumatology Scientific Meeting; San
Francisco, CA; Oct. 24-29, 2008.

Terkeltaub, et al.; "The Clinical Relevance of P-gp and CYP 3A4 on
Colchicine Metabolism and Elimination"; Presentation at the Ameri-
can College of Rheumatology Scientific Meeting; San Francisco,
CA; Oct. 24-29, 2008.

Brooks; "Rheumatic Disorders" chapter 25 of Avery's Drug Therapy,
pub. 1997 by Adis International, pp. 1113-1161.

Hung et al.; "Fatal Interaction Between Clarithromycin And
Colchicines In Patients With Renal Insufficiency: A Retrospective
Study"; Clarithromycin And Colchicine Interaction; 41; pp. 291-300
(2005).

Krishnan, et al.; "Gout in Ambulatory Care Settings in the United
States"; Journal of Rheumatology; 35; pp. 498-501; (2008).

Clarithromycin Tablets, USP; Clarithromycin for Oral Suspension,
USP, BIAVIN XL Filmtab; Abbott Laboratories; 07E-010-U780-4
Master; 26 pages; Reference 03-5569-R3 Revised Mar. 2007.

U.S. Appl. No. 12/368,700 Non-final Office Action dated Apr. 27,
2009, 77 pages.

Leiken et al., "Colchicine"; Poisoning and Toxicology Handbook
(4th Ed.), Aug. 2007, p. 216.

* cited by examiner

Primary Examiner—Sreeni Padmanabhan

Assistant Examiner—Umamaheswari Ramachandran

(74) *Attorney, Agent, or Firm*—Cantor Colburn LLP

(57) **ABSTRACT**

Methods for concomitant administration of colchicine
together with one or more macrolide antibiotics, e.g.,
clarithromycin or erythromycin, are disclosed. Such methods
reduce the dangers commonly associated with such concomi-
tant administration and provide additional benefits. Methods
of notifying health care practitioners and patients regarding
appropriate dosing for co-administration of colchicine
together with macrolide antibiotics are also provided.

8 Claims, 2 Drawing Sheets